- Home
- RGR vs CTNM Comparison
RGR vs CTNM Comparison
Compare RGR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGR | CTNM |
|---|---|---|
| Founded | 1949 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.9M | 507.0M |
| IPO Year | 1994 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RGR | CTNM |
|---|---|---|
| Price | $43.53 | $13.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $43.00 | $19.00 |
| AVG Volume (30 Days) | 152.2K | ★ 322.2K |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $546,057,000.00 | N/A |
| Revenue This Year | $2.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.94 | N/A |
| 52 Week Low | $28.33 | $3.35 |
| 52 Week High | $48.21 | $16.33 |
Technical Indicators
Market Signals| Indicator | RGR | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 75.69 | 47.54 |
| Support Level | $35.42 | $10.39 |
| Resistance Level | $45.33 | $15.80 |
| Average True Range (ATR) | 1.26 | 1.11 |
| MACD | 0.36 | -0.13 |
| Stochastic Oscillator | 95.84 | 44.15 |
Price Performance
Historical ComparisonAbout RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.